ContraVir Pharmaceuticals Announces $9.0 Million Private Placement
Sichenzia Ross Friedman Ference LLP Advises ContraVir Pharmaceuticals on $9.0 Million Private Placement
New York, October 28, 2014 (Global Newswire) – New York based securities law firm Sichenzia Ross Friedman Ference LLP announced that it has represented ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, on a $9 million private placement consisting of Series A Convertible Preferred stock to a non-U.S investor.
Pursuant to the private placement, the Series A Preferred Stock can be converted into shares of common stock at the conversion price of $0.48 per share. The Sichenzia Ross Friedman Ference LLP team was led by partner Jeffrey J. Fessler.
- Sichenzia Ross Ference Carmel LLP 代表 WallachBeth Capital LLC 和 Revere Securities LLC 参与 Trident Digital Tech Holdings Ltd 的 900 万美元首次公开发行。 - September 11, 2024
- Sichenzia Ross Ference Carmel LLP 代表 EF Hutton 参与 Solidion Technology, Inc. 400 万美元的私募交易。 - September 9, 2024
- Sichenzia Ross Ference Carmel LLP 代表 Joseph Gunnar & Co, LLC 参与 Eastside Distilling 的 40 万美元注册直接发行 - September 6, 2024